EXEL
Exelixis Inc

12,207
Mkt Cap
$10.24B
Volume
3.86M
52W High
$49.62
52W Low
$27.86
PE Ratio
18.25
EXEL Fundamentals
Price
$38.05
Prev Close
$36.08
Open
$36.27
50D MA
$38.69
Beta
0.46
Avg. Volume
2.57M
EPS (Annual)
$1.76
P/B
5.05
Rev/Employee
$1.89M
Loading...
Loading...
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc...
PR Newswire·17h ago
News Placeholder
More News
News Placeholder
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT...
Business Wire·2d ago
News Placeholder
The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners
The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners The Institute for Follicular...
PR Newswire·3d ago
News Placeholder
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq) versus...
Business Wire·4d ago
News Placeholder
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX (cabozantinib) versus placebo in patients with previously...
Business Wire·6d ago
News Placeholder
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·15d ago
News Placeholder
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·16d ago
News Placeholder
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·2mo ago
News Placeholder
Do Options Traders Know Something About Exelixis Stock We Don't?
Investors need to pay close attention to EXEL stock based on the movements in the options market lately.
Zacks·2mo ago
News Placeholder
Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·2mo ago

Latest EXEL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.